MMJ PhytoTech receives clinical trial approval
Published 24-AUG-2015 15:14 P.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
ASX-listed biotech player MMJ PhytoTech (ASX:MMJ) is aiming to kick off clinical trials of its cannabinoid oral capsule to help stave off the effects of multiple sclerosis (MS) – and says results from the trial could be received as early as the first quarter 2016.
The vertically integrated biotech company told the market this morning that its efforts to gain regulatory approval for clinical trials for its pill in Israel had paid off, with the company’s Israeli subsidiary now able to conduct testing.
It is hoping the pill, which is under development in Israel, will help relieve pain and spasticity related to MS.
About MMJ PhytoTech
MMJ PhytoTech recently completed a merger and $4.8 million placement to make it the first truly vertically integrated medical cannabis company listed on the ASX.
It grows cannabis plants in Canada, with the main aim to extract the vital medicinal ingredients of the plant.
This will aid the company in becoming a pharmaceutical developer and distributor of cannabinoid “Active Pharmaceutical Ingredients” (APIs), which are highly valuable and for cannabinoid (CBD), can be traded at prices upwards of $350,000 per kilogram.
The newly minted company’s United Greeneries offshoot is expecting regulatory approval in Canada to start producing up to 700kg of medical cannabis in the fourth quarter for its Duncan Facility.
It also has a second project in the works in Canada, which could bring production up to 12,000kg per year.
United Greeneries is fully integrated with a state-of-the-art biochemical quality testing and analytics laboratory at its disposal. This is vital, as while it’s a requirement under Canadian law, not a lot of growers have this at their disposal.
It derives compounds such as cannabidiol from cannabis at its Swiss subsidiary Satipharm, which is focused on the delivery of both diet supplement pills made from synthesised materials and the delivery of those materials at commercial quantities.
It told the market last month that it would start to sell a minimum of 30,000 capsules each per month, and this amount would increase to 135,000 per month.
If any indications are a guide, MMJ is feeling bullish about its prospects, with pills going for €3 ($A4.50) each, delivering a minimum €90,000 in revenue per month and a possible €405,000 per month in the offing.
It is also eyeing up being a key supplier of pharmaceutical grade quantities of things such as Tetrahydrocannabinol, Tetrahydrocannabinolic Acid, Cannabidoil, Cannabidiolic Acid.
If you don’t know what any of those things are, don’t worry – you’re not alone.
All you need to know is that the ingredients are used in research, product development, and processing by other companies and there’s a shortage of bulk amounts of these ingredients in pharmaceutical grade quality.
These ingredients can also go for as high as $350,000 per kg, and in some cases MMJ Phytotech is producing up to 20kg per month of these ingredients.
In Israel, subsidiary PhytoTech Therapeutics has been focused on the development of medical products using cannabidiol and other products derived from cannabis.
The Israeli work
The receipt for approvals for its phase one trial is undoubtedly a boon for the company, which also recently conducted temperature stability trials for its product.
It found that the product have a long shelf life when stored at room temperature, increasing its commercial viability in its current form, as it reduces the costs of shipping and storage.
Meanwhile, in order to get up to commercial speed as soon as possible, MMJ told investors that it was in discussions to obtain commercial quantities of key ingredients and it was also talking to “one of the leading GMP manufacturers worldwide” for supply of soft gelatin capsules.
The news comes off the back of a recently completed merger between MMJ and PhytoTech, an oversubscribed placement of $4.8 million and the resignation of Boaz Wachtel, executive director and head of international business development.
Managing director Andreas Gedeon has also been promoted as part of a board re-shuffle, taking on the CEO role for the merged group.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.